- Home
- DHIL vs ADCT Comparison
DHIL vs ADCT Comparison
Compare DHIL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- ADCT
- Stock Information
- Founded
- DHIL 1990
- ADCT 2011
- Country
- DHIL United States
- ADCT Switzerland
- Employees
- DHIL N/A
- ADCT N/A
- Industry
- DHIL Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- ADCT Health Care
- Exchange
- DHIL Nasdaq
- ADCT Nasdaq
- Market Cap
- DHIL 384.0M
- ADCT 380.2M
- IPO Year
- DHIL 1995
- ADCT 2020
- Fundamental
- Price
- DHIL $128.35
- ADCT $4.46
- Analyst Decision
- DHIL
- ADCT Strong Buy
- Analyst Count
- DHIL 0
- ADCT 6
- Target Price
- DHIL N/A
- ADCT $7.60
- AVG Volume (30 Days)
- DHIL 27.0K
- ADCT 984.4K
- Earning Date
- DHIL 10-30-2025
- ADCT 11-07-2025
- Dividend Yield
- DHIL 4.67%
- ADCT N/A
- EPS Growth
- DHIL N/A
- ADCT N/A
- EPS
- DHIL 17.21
- ADCT N/A
- Revenue
- DHIL $149,665,296.00
- ADCT $77,246,000.00
- Revenue This Year
- DHIL N/A
- ADCT $11.78
- Revenue Next Year
- DHIL N/A
- ADCT $4.83
- P/E Ratio
- DHIL $7.46
- ADCT N/A
- Revenue Growth
- DHIL 2.65
- ADCT 15.73
- 52 Week Low
- DHIL $122.32
- ADCT $1.05
- 52 Week High
- DHIL $173.25
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- DHIL 30.76
- ADCT 59.09
- Support Level
- DHIL $123.64
- ADCT $3.92
- Resistance Level
- DHIL $138.94
- ADCT $4.80
- Average True Range (ATR)
- DHIL 2.60
- ADCT 0.25
- MACD
- DHIL -0.91
- ADCT 0.00
- Stochastic Oscillator
- DHIL 27.69
- ADCT 61.36
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).